A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2019
Price : $35 *
At a glance
- Drugs Licogliflozin (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- Sponsors Novartis; Novartis Pharmaceuticals
- 24 Sep 2019 Planned End Date changed from 3 Dec 2019 to 5 Dec 2019.
- 24 Sep 2019 Planned primary completion date changed from 5 Nov 2019 to 5 Dec 2019.
- 24 Sep 2019 Status changed from recruiting to active, no longer recruiting.